Metabolic / incretin
Tirzepatide
Also known as LY3298176
A dual GIP and GLP-1 receptor agonist, the reference dual-incretin standard preceding triple agonists like retatrutide.
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors and a common comparator in incretin-receptor research. It is frequently studied side-by-side with semaglutide (mono GLP-1) and retatrutide (triple agonist) in receptor-engagement assays.
Common research areas
- Dual-incretin receptor studies
- Comparative GLP-1-class assays
Watch
GLP-1 Receptor Agonists: Mechanisms of Action (Semaglutide & Tirzepatide)
Dr. Yan Yu, MD CCFPYouTube ↗
In our catalog
Tirzepatide 20 mg · $50 CAD · ≥99% HPLC
Related compounds
Selected references
- 1. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne), 2024. PMID 39114288
- 2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022. PMID 35579691
- 3. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol, 2022. PMID 36050763
For laboratory research use only. Reference information, not usage guidance or dosing advice.